Metformin and cancer: Mounting evidence against an association

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1786-1788

  Suissa, Samy ^a,b   Azoulay, Laurent ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL ASSESSMENT; DRUG EFFECT; DRUG SAFETY; HUMAN; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRESCRIPTION; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; URINARY BLADDER NEOPLASMS;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METFORMIN; SULFONYLUREA COMPOUNDS; URINARY BLADDER NEOPLASMS;

EID: 84903534977     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0500     Document Type: Note

References (22)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
2. Cusi K, DeFronzo RA. Metformin: a review of itsmetabolic effects. Diabetes Rev 1998;6:89-131
3. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305 (Pubitemid 40813563)
4. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013;62:922-934
5. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778-790
6. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 2009;18:701-705
7. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009;27:3271-3273
8. Goodwin PJ, Stambolic V, Lemieux J, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126:215-220
9. Higurashi T, Takahashi H, Endo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer 2012;12:118
10. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673
11. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53 (Pubitemid 37046632)
12. Suissa S, Ernst P. Bias in observational study of the effectiveness of nasal corticosteroids in asthma. J Allergy Clin Immunol 2005;115:714-719 (Pubitemid 40460844)
13. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-249 (Pubitemid 46431687)
14. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492-499 (Pubitemid 351264145)
15. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20
16. Mamtani R, Pfanzelter N, Haynes K, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 2014;37:1910-1917
17. Azoulay L, Dell' Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:337-344
18. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2013;22:1877-1883
19. Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129
20. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013;36:3018-3026
21. Margel D, Urbach D, Lipscombe LL, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013;105:1123-1131
22. Suissa S. Randomized trials built on sand: examples from COPD, hormone therapy, and cancer. Rambam Maimonides Med J 2012;3:e0014